Stem Cell Educator Therapy May Help Fight Diabetes

This article originally appeared here.
Share this content:
Stem Cell Educator Therapy May Help Fight Diabetes
Stem Cell Educator Therapy May Help Fight Diabetes

MONDAY, July 17, 2017 (HealthDay News) -- Stem cell educator therapy may provide long term benefits in type 1 and type 2 diabetes, according to a study published online July 7 in Stem Cells Translational Medicine.

Yong Zhao, M.D., Ph.D., an associate scientist at the Hackensack University Medical Center in New Jersey, and colleagues looked at four years of data on nine type 1 diabetes patients in China. Two individuals with type 1 diabetes who received a stem cell educator treatment shortly after diagnosis (five and eight months later) still had normal C-peptide production and didn't need insulin four years after a single treatment. Another type 1 patient had had the disease for four years when she received treatment. She still had improvements in her C-peptide levels, but wasn't considered in remission. The remaining six patients with type 1 saw decreases in their C-peptide levels over time.

The researchers also looked at six patients with severe, long-standing (15 to 24 years) type 2 diabetes. They found that one treatment helped four patients achieve normal C-peptide levels and maintain them over the four-year follow-up. "For the four type 2 patients, their C-peptide is very stable after one treatment," Zhao told HealthDay.

"Stem cell educator therapy is a safe approach" with long-term effectiveness, said Zhao. In addition to helping people with diabetes, Zhao said the treatment could help with other autoimmune diseases, possibly including alopecia areata, lupus, Hashimoto's thyroiditis, and Sjogren's syndrome.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Gene Tx Approved for Certain Types of B-Cell Lymphoma

Gene Tx Approved for Certain Types of B-Cell ...

First such treatment for certain types of non-Hodgkin lymphoma

Uninsurance Down by One-Third for Cancer Diagnoses in 2014

Uninsurance Down by One-Third for Cancer Diagnoses in ...

Significant decreases in uninsurance seen across all stages and sites assessed in first year of ACA

Diabetes Ups Risk of MACE in Acute Coronary Syndromes

Diabetes Ups Risk of MACE in Acute Coronary ...

Diabetes, but not pre-diabetes, tied to increased risk of major adverse cardiac events in adjusted model

is free, fast, and customized just for you!

Already a member?

Sign In Now »